Finoriq research workspace
BIOLIFE SOLUTIONS INC (BLFS) Company Overview
BioLife Solutions, Inc. develops, manufactures, and markets bioproduction products and services for the. Review BLFS filings, fundamentals, valuation, and ownership on Finoriq.
Company Snapshot
BioLife Solutions, Inc. develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction products, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; CryoCase cryo-compatible transparent rigid containers for closed-system fill and retrieval, and automated cell processing machines; and the ThawSTAR line include automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.
- Company
- BIOLIFE SOLUTIONS INC (BLFS)
- Ticker
- BLFS
- Market Cap
- $1.4B
- Latest Price
- $29.13
- Industry
- Medical Devices
BIOLIFE SOLUTIONS INC (BLFS) Current Valuation Metrics
Static valuation preview for BIOLIFE SOLUTIONS INC (BLFS). Market data retrieved 2026-07-08. Filing currency USD.
| Metric | Value | Source |
|---|---|---|
| P/SMarket cap divided by latest TTM revenue. | 13.4x | Revenue | TTM Q1 2026 |
| P/Operating Cash FlowMarket cap divided by latest TTM operating cash flow. | 74.5x | Operating Cash Flow | TTM Q1 2026 |
| Earnings YieldLatest TTM net income divided by market cap. | -0.22% | Net Income | TTM Q1 2026 |
| Operating Cash Flow YieldLatest TTM operating cash flow divided by market cap. | 1.3% | Operating Cash Flow | TTM Q1 2026 |
| Price / BookMarket cap divided by stockholders' equity. | 3.58x | Stockholders' Equity | Q1 2026 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.